The evolution of T-DXd from a primarily HER2-targeting ADC to one that is also effective against HER2-low cancers represents a significant breakthrough for chemo-refractory HR-negative and HR-positive/HER2-negative breast cancers that fit the HER2-low category and previously had limited therapeutic options. Here, ERBB2 is linked to breast carcinoma.